Plasma profiling determinants of matrix homeostasis in paediatric dilated cardiomyopathy

Cardiology in the Young

Volumn 21, Issue 1, 2011, Pages 52-61

  Hsia, Tain Yen ^a   Ringewald, Jeremy M ^a   Stroud, Robert E ^a   Roessler, Nadia ^a   Kumar, Nidhi ^a   Reeves, Scott T ^a   Spinale, Francis G ^a,b  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

biomarker; Cardiac failure; myocardial; plasma; remodelling

Indexed keywords

GELATINASE A; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ADOLESCENT; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; BLOOD VOLUME; CHILD; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; HIGH THROUGHPUT MULTIPLEX SUSPENSION IMMUNOASSAY; HUMAN; IMMUNOASSAY; INFANT; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; HOMEOSTASIS; HUMANS; INFANT; MATRIX METALLOPROTEINASES; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 79952899048     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951110001381     Document Type: Article

References (32)

1. Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006; 296: 1867-1876. (Pubitemid 44596196)
2. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol Rev 2007; 87: 1285-1342. (Pubitemid 350041472)
3. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF Jr. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol 1996; 148: 1639-1648. (Pubitemid 26135903)
4. Spinale FG. Matrix metalloproteinases: Regulation and dysregulation in the failing heart. Circ Res 2002; 90: 520-530. (Pubitemid 34640901)
5. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102: 1944-1949.
6. Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases/ tissue inhibitors of metalloproteinases: Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113: 2089-2096.
7. Wilson EM, Gunasinghe HR, Coker ML, et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 2002; 8: 390-398. (Pubitemid 36055741)
8. George J, Patal S, Wexler D, Roth A, Sheps D, Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase- 3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 2005; 150: 484-487. (Pubitemid 41317618)
9. Frantz S, Stork S, Michels K, et al. Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: An independent predictor of mortality. Eur J Heart Fail 2008; 10: 388-395.
10. Gottschalk PG, Dunn JR. The five-parameter logistic: A characterization and comparison with the four-parameter logistic. Anal Biochem 2005; 343: 54-65. (Pubitemid 40978609)
11. Bigg HF, Shi YE, Liu YE, Steffensen B, Overall CM. Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2. J Biol Chem 1997; 272: 15496-15500. (Pubitemid 27255577)
12. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996; 271: 30375-30380. (Pubitemid 26404039)
13. Cheung C, Luo H, Yanagawa B, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in coxsackievirusinduced myocarditis. Cardiovasc Pathol 2006; 15: 63-74.
14. Li YY, Feldman AM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998; 98: 1728-1734. (Pubitemid 28492492)
15. Yokoseki O, Yazaki Y, Suzuki J, Imamura H, Takenaka H, Isobe M. Association of matrix metalloproteinase expression and left ventricular function in idiopathic dilated cardiomyopathy. Jpn Circ J 2000; 64: 352-357. (Pubitemid 30321965)
16. Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer BE. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 2002; 4: 439-444. (Pubitemid 36564961)
17. Jordan A, Roldan V, Garcia M, et al. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: Relation to functional data and prognosis. J Intern Med 2007; 262: 385-392. (Pubitemid 47246973)
18. Kelly D, Khan SQ, Thompson M, et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: Novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J 2008; 29: 2116-2124.
19. Yan AT, Yan RT, Spinale FG, et al. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail 2006; 12: 514-519. (Pubitemid 44316923)
20. Sundstrom J, Evans JC, Benjamin EJ, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: The Framingham Heart Study. Circulation 2004; 109: 2850-2856. (Pubitemid 38786446)
21. Lubos E, Schnabel R, Rupprecht HJ, et al. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: Results from the AtheroGene study. Eur Heart J 2006; 27: 150-156. (Pubitemid 43069030)
22. Sundstrom J, Evans JC, Benjamin EJ, et al. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: The Framingham heart study. Eur Heart J 2004; 25: 1509-1516. (Pubitemid 39165629)
23. Noji Y, Shimizu M, Ino H, et al. Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction. Circ J 2004; 68: 355-360. (Pubitemid 38470711)
24. Overall CM, Butler GS. Protease yoga: Extreme flexibility of a matrix metalloproteinase. Structure 2007; 15: 1159-1161. (Pubitemid 47539171)
25. Picard F, Brehm M, Fassbach M, et al. Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients. Clin Res Cardiol 2006; 95: 261-269.
26. Yarbrough WM, Mukherjee R, Brinsa TA, et al. Matrix metalloproteinase inhibition modifies left ventricular remodeling following myocardial infarction. J Thorac Cardiovasc Surg 2003; 125: 602-610. (Pubitemid 36373906)
27. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 2003; 92: 827-839. (Pubitemid 36542523)
28. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008; 40: 1362-1378.
29. Cuenca J, Martín-Sanz P, Alvarez-Barrientos AM, Boscá L, Goren N. Infiltration of inflammatory cells plays an important role in matrix metalloproteinase expression and activation in the heart during sepsis. Am J Pathol 2006; 169: 1567-1576. (Pubitemid 351181989)
30. Fitzsimmons PJ, Forough R, Lawrence ME, et al. Urinary levels of matrix metalloproteinase 9 and 2 and tissue inhibitor of matrix metalloproteinase in patients with coronary artery disease. Atherosclerosis 2007; 194: 196-203. (Pubitemid 47464300)
31. Lauhio A, Sorsa T, Srinivas R, et al. Urinary matrix metalloproteinase- 8, -9, -14 and their regulators (TRY-1, TRY-2, TATI) in patients with diabetic nephropathy. Ann Med 2008; 40: 312-320. (Pubitemid 351563934)
32. Tziakas DN, Chalikias GK, Papaioakeim M, et al. Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy. Am J Cardiol 2005; 96: 1449-1451. (Pubitemid 41566631)